SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3429-3436

  Dieterich, Douglas ^a   Asselah, Tarik ^b   Guyader, Dominique ^c   Berg, Thomas ^d   Schuchmann, Marcus ^e   Mauss, Stefan ^f   Ratziu, Vlad ^g   Ferenci, Peter ^h   Larrey, Dominique ⁱ   Maieron, Andreas ^j   Stern, Jerry O ^k   Ozan, Melek ^k   Datsenko, Yakov ^l   Böcher, Wulf Otto ^l   Steinmann, Gerhard ^l  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e Klinik für Innere Medizin   (Germany)

^f Center for HIV and Hepatogastroenterology   (Germany)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ HÔPITAL SAINT ELOI   (France)

^j ELISABETHINEN HOSPITAL   (Austria)

^k BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^l BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FALDAPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; CARRIER PROTEIN; MACROGOL DERIVATIVE; N-((CYCLOPENTYLOXY)CARBONYL)-3-METHYLVALYL-4-((8-BROMO-7-METHOXY-2-(2-((2-METHYLPROPANOYL)AMINO)-1,3-THIAZOL-4-YL)QUINOLIN-4-YL)OXY)-N-(1-CARBOXY-2-ETHENYLCYCLOPROPYL)PROLINAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; OLIGOPEPTIDE; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE; VIRAL PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPOTHYROIDISM; LIVER CIRRHOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OPEN STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84901249508     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02497-13     Document Type: Article

References (26)

1. Afdhal NH. 2004. The natural history of hepatitis C. Semin. Liver Dis. 24(Suppl 2):3-8. http://dx.doi.org/10.1055/s-2004-832922.
2. Thompson CJ, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K. 2007. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol. Assess. 11:1-206.
3. Merck Sharp and Dohme Corp. 2013. Victrelis (boceprevir) prescribing information. Merck Sharp and Dohme Corp., Whitehouse Station, NJ.
4. Vertex Pharmaceuticals Incorporated. 2013. Incivek (telaprevir) highlights of US prescribing information. Vertex Pharmaceuticals Incorporated, Cambridge, MA.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
6. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski M, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JC, Bronowicki J-P, SPRINT-2 Investigators. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
7. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, ILLUMINATE Study Team. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365:1014-1024. http://dx.doi.org/10.1056/NEJMoa1014463.
8. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group. 2013. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)- NCT01514890. J. Hepatol. 59:434-441. http://dx.doi.org/10.1016/j. jhep.2013.04.035.
9. Martel-LaFerrière V, Bichoupan K, Pappas A, Schonfeld E, Ng M, Sefcik R, Vachon M-L, Standen M, Perumalswami P, Schiano TD, Odin JA, Liu L, Dieterich DT, Branch AD. 2012. Effectiveness of HCV triple therapy with telaprevir in New York city. J. Hepatol. 56(Suppl 2):S449. http://dx.doi.org/10. 1016/S0168-8278(12)61150-7.
10. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1207-1217. http://dx.doi.org/10.1056/NEJMoa1009482.
11. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team. 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364:2417-2428. http://dx.doi.org/10.1056/NEJMoa1013086.
12. Asselah T, Marcellin P. 2012. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 32(Suppl 1): 88-102. http://dx.doi.org/10.1111/j.1478-3231.2011.02699.x.
13. Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, White PW, Stern JO, Steinmann G, Yong CL, Kukolj G, Scherer J, Böcher WO. 2011. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 54:1114-1122. http://dx.doi.org/10.1016/j.jhep.2010.08. 040.
14. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. 2013. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 57:2143-2154. http://dx.doi.org/10.1002/hep. 26276.
15. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 Investigators. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716. http://dx.doi.org/10.1016/S0140- 6736(10)60934-8.
16. Poordad FF. 2010. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment. Pharmacol. Ther. 31:1251-1267. http://dx.doi.org/10.1111/j.1365-2036.2010.04300.x.
17. Estrabaud E, Vidaud M, Marcellin P, Asselah T. 2012. Genomics and HCVinfection: progression of fibrosis and treatment response. J. Hepatol. 57:1110-1125. http://dx.doi.org/10.1016/j.jhep.2012.05.016.
18. Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. 2013. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype- 1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 57: 2155-2163. http://dx.doi.org/10.1002/hep.26386.
19. Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour J-F, Bourlière M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Stern JO, Datzenko Y, Scherer J, Quinson A-M. 2013. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial. J. Hepatol. 58(Suppl 1):S569-S570. http://dx.doi.org/10.1016/ S0168-8278(13)61415-4.
20. Lagacé L, White PW, Bousquet C, Dansereau N, Dô F, Llinas-Brunet M, Marquis M, Massariol MJ, Maurice R, Spickler C, Thibeault D, Triki I, Zhao S, Kukolj G. 2012. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 56:569-572. http://dx.doi.org/10.1128/AAC.05166-11.
21. Berger K, Bethell R, Cartier M, Marquis M, Triki I, Böcher WO, Datsenko Y, Steinmann GG, Scherer J, Stern JO, Kukolj G. 2012. Analysis of baseline polymorphisms and persistence of emergent variants from phase Ib and II trials evaluating the HCV NS3 protease inhibitor BI 201335. Hepatology 56(Suppl 1):785.
22. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc- Cone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593. http://dx.doi.org/10.1056/NEJMoa0808010.
23. Sane R, Podila L, Mathur A, Mease K, Taub M, Huang Q, Elgadi M, Nehmiz G, Steinmann G. 2011. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J. Hepatol. 54(Suppl 1):S488. http://dx.doi.org/10.1016/S0168-8278(11)61238-5.
24. Sulkowski MS. 2003. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver. Dis. 23:183-194. http://dx.doi.org/10.1055/s-2003-39949.
25. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. 2013. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58:1918-1929. http://dx.doi.org/10.1002/hep.26641.
26. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. 2010. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 52(Suppl 1):278.